Insider trade

Edwards Lifesciences (EW): Officer had shares withheld for tax 1,141 shares

Daveen Chopra, Officer at Edwards Lifesciences, reported a tax withholding of 1,141 shares.

1,141
Shares · @ $82.76
Traded
May 8, 2026
Filed
May 9, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 11, 2026Insider · 2 peopleInsiders: 3 sales (~$1.2M)
  2. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  3. Mar 27, 2026FDARecall: Edwards EVOQUE tricuspid delivery system REF:9850TDS Sterile EO
  4. Mar 27, 2026CongressDisclosed purchase of EW — reported range $1,001 - $15,000
  5. Apr 2, 2026Insider · 1 personInsiders: 2 sales (~$1.8M)
  6. Apr 6, 2026InsiderOfficer sold ~$83K of EW shares in the open market
  7. Apr 9, 2026Insider · 1 personInsiders: 2 sales (~$1.0M)
  8. Apr 17, 2026FDAFDA device clearance: Edwards eSheath+ introducer set
  9. Apr 23, 2026Company filing · Form 8-K · ResultsReported its results
  10. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  11. May 1, 2026Insider · 1 personInsiders: 2 sales (~$85K)
  12. May 2, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.”
  13. May 4, 2026InsiderOfficer sold ~$86K of EW shares in the open market
  14. May 7, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“of Certain Officers Approval of the Amended and Restated Long-Term Stock Incentive Compensation Program At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved the amendment and restatement of the Company’s Long-Term Stock Incentive Compensation Program (the “Long-Term Stock Program”).”

What came next

  1. May 11, 2026InsiderOfficer sold ~$47K of EW shares in the open market
  2. May 12, 2026Insider · 1 personInsiders: 2 sales (~$2.8M)
  3. May 15, 2026Insider · 1 personInsiders: 2 sales (~$1.5M)
  4. May 18, 2026InsiderOfficer sold ~$50K of EW shares in the open market
  5. May 22, 2026InsiderOfficer sold ~$127K of EW shares in the open market
  6. May 27, 2026InsiderOfficer sold ~$2M of EW shares in the open market
  7. May 29, 2026InsiderOfficer sold ~$49K of EW shares in the open market
  8. Jun 5, 2026FDAFDA device clearance: Fogarty Spring Clips, Handleless Clamps, and Clamp Inserts
  9. Jun 11, 2026FDAFDA device clearance: Respiration Rate algorithm
  10. Jun 17, 2026InsiderCEO sold ~$46K of EW shares in the open market
  11. Jun 26, 2026FDAFDA device clearance: ECLIPTIS Left Atrial Appendage Exclusion System (ECS135); ECLIPTIS Left Atrial Appendage Exclusion System (ECS140); ECLIPTIS Left Atrial Appendage Exclusion Sy…
  12. Jun 30, 2026InsiderOfficer sold ~$57K of EW shares in the open market
  13. Jul 10, 2026InsiderOfficer sold ~$57K of EW shares in the open market
  14. Jul 23, 2026Company filing · Form 8-K · ResultsReported its results
  15. Jul 23, 2026Government · Federal Register noticeUnited States v. Edwards LifeSciences Corp. and Genesis MedTech Group Limited; Proposed Final Judgment and Competitive Impact Statement
  16. Jul 27, 2026InsiderCEO sold ~$245K of EW shares in the open market
  17. Jul 28, 2026InsiderOfficer sold ~$819K of EW shares in the open market
  18. Jul 30, 2026InsiderOfficer sold ~$13K of EW shares in the open market
  19. Aug 11, 2026InsiderOfficer sold ~$57K of EW shares in the open market
  20. Aug 25, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Edwards Lifesciences

For Edwards Lifesciences, OQRO holds 14 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EW page.

Other recent filings by Daveen Chopra, CVP, TMTT & Surgical

The full history of Daveen Chopra, CVP, TMTT & Surgical is on the profile page.

How this filing works

Explore the data

Common questions

Which Edwards Lifesciences (EW) insider traded, and how much?

Daveen Chopra, Officer at Edwards Lifesciences, reported a tax withholding of 1,141 shares. At $82.76.

When did it happen, and when was it made public?

Traded: May 8, 2026. Filed: May 9, 2026. That is 1 day between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Edwards Lifesciences recently?

For Edwards Lifesciences, OQRO holds 14 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the EW page.

Does this mean EW stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Edwards Lifesciences

Everything OQRO holds on this company is on its EW page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data